Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 5, 2007, Pages 398-405

  Steel, Jason C ^a,b   Cavanagh, Heather M A ^a   Burton, Mark A ^a   Abu Asab, Mones S ^b   Tsokos, Maria ^b   Morris, John C ^b   Kalle, Wouter H J ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; AL complexes; Immuno protection; Liposomes; Neutralizing antibodies

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; LIPOSOME; PENTOBARBITAL; SODIUM CHLORIDE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EMBRYO; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; BETA-GALACTOSIDASE; CELL LINE, TUMOR; GENES, REPORTER; GENETIC VECTORS; HUMANS; LIPOSOMES; MOLECULAR CONFORMATION; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; QUATERNARY AMMONIUM COMPOUNDS; RATS; SALIVARY GLAND NEOPLASMS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

EID: 33947354213     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.12.004     Document Type: Article

References (37)

1. Alemany R., and Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8 (2001) 1347-1353
2. Barnett B., Crews C., and Douglas J. Targeted adenoviral vectors. Biochim. Biophys. Acta 1575 (2002) 1-14
3. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., and Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997) 1320-1323
4. Breyer B., Jiang W., Cheng H., Zhou L., Paul R., Feng T., and He T. Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1 (2001) 149-162
5. Croyle M., Anderson D., Roessler B., and Amidon G.L. Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. Pharm. Dev. Technol. 3 (1998) 365-372
6. Dass C.R., Walker T., and Burton M.A. Liposomes containing cationic dimethyl dioctadecyl ammonium bromide: formulation, quality control, and lipofection efficiency. Drug Deliv. 9 (2002) 11-18
7. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., and Wickham T.J. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75 (2001) 11284-11291
8. Fukuhara H., Hayashi Y., Yamamoto N., Fukui T., Nishikawa M., Mitsudo K., Tohnai I., Ueda M., Mizuno M., and Yoshida J. Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines. Oral. Oncol. 39 (2003) 601-609
9. Hemmi S., Geertsen R., Mezzacasa A., Peter I., and Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9 (1998) 2363-2373
10. Imperiale M., and Kochanek S. Adenovirus vectors: biology, design, and production. Curr. Top. Microbiol. Immunol. 273 (2004) 335-357
11. Lee E.M., Hong S.H., Lee Y.J., Kang Y.H., Choi K.C., Choi S.H., Kim I.H., and Lim S.J. Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J. Cancer Res. Clin. Oncol. 130 (2004) 169-177
12. Leissner P., Legrand V., Schlesinger Y., Hadji D.A., van Raaij M., Cusack S., Pavirani A., and Mehtali M. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8 (2001) 49-57
13. Li Y., Pong R.C., Bergelson J.M., Hall M.C., Sagalowsky A.I., Tseng C.P., Wang Z., and Hsieh J.T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59 (1999) 325-330
14. Lohr F., Huang Q., Hu K., Dewhirst M.W., and Li C.Y. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin. Cancer Res. 7 (2001) 3625-3628
15. Mizuguchi H., and Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther. 9 (2002) 236-242
16. Mizuguchi H., and Hayakawa T. Targeted adenovirus vectors. Hum. Gene Ther. 15 (2004) 1034-1044
17. Natsume A., Mizuno M., Ryuke Y., and Yoshida J. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity. Jpn. J. Cancer Res. 91 (2000) 363-367
18. Nazarenko D., Dertinger S., and Gasiewicz T. Enhanced detection of beta-galactosidase reporter activation is achieved by a reduction of hemoglobin content in tissue lysates. Biotechniques 30 (2001) 776-781
19. Nomura T., Nakajima S., Kawabata K., Yamashita F., Takakura Y., and Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 57 (1997) 2681-2686
20. Pelisek J., Armeanu S., and Nikol S. Evaluation of beta-galactosidase activity in tissue in the presence of blood. J. Vasc. Res. 37 (2000) 585-593
21. Russell W.C. Update on adenovirus and its vectors. J. Gen. Virol. 81 (2000) 2573-2604 (review)
22. Ryuke Y., Mizuno M., Natsume A., and Yoshida J. Transduction efficiency of adenoviral vectors into human glioma cells increased by association with cationic liposomes. Neurol. Med. Chir. 40 (2000) 256-260
23. Schagen F.H.E., Ossevoort M., Toes R.E.M., and Hoeben R.C. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit. Rev. Oncol. Hematol. 50 (2004) 51-70
24. Steel J.C., Cavanagh H.M., Burton M.A., and Kalle W.H.J. Microsphere-liposome complexes protect adenoviral vectors from neutralizing antibody without losses in transfection efficiency, in vitro. J. Pharm. Pharmacol. 56 (2004) 1371-1378
25. Steel J.C., Cavanagh H.M., Burton M.A., Dingwall D., and Kalle W.H.J. In-vitro evaluation of ion-exchange microspheres for the sustained release of liposomal-adenoviral conjugates. J. Control Rel. 95 (2004) 601-611
26. Steel J.C., Kalle W.H.J., Dingwall D.J., Cavanagh H.M., and Burton M.A. Pre-treatment with a non-therapeutic dose of cisplatin increases solid tumour response to liposomal-p53 gene therapy-an in vivo study. Cancer Ther. 2 (2004) 239-244
27. Steel J.C., Cavanagh H.M., Burton M.A., Dingwall D.J., and Kalle W.H.J. Modification of liposomal concentration in liposome/adenoviral complexes allows significant protection of adenoviral vectors from neutralizing antibody, in vitro. J. Virol. Methods 126 (2005) 31-36
28. Stewart P., Fuller S., and Burnett R. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J. 12 (1993) 2589-2599
29. Takakuwa K., Fujita K., Kikuchi A., Sugaya S., Yahata T., Aida H., Kurabayashi T., Hasegawa I., and Tanaka K. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. Jpn. J. Cancer Res. 88 (1997) 166-175
30. Toyoda K., Ooboshi H., Chu Y., Fasbender A., Davidson B.L., Welsh M.J., and Heistad D.D. Cationic polymer and lipids enhance adenovirus-mediated gene transfer to rabbit carotid artery. Stroke 29 (1998) 2181-2188
31. Tsujinoue H., Kuriyama S., Tominaga K., Okuda H., Nakatani T., Yoshiji H., Tsujimoto T., Akahane T., Asada K., and Fukui H. Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats. Int. J. Oncol. 18 (2001) 575-580
32. Walker T.L., White J.D., Esdale W.J., Burton M.A., and DeCruz E.E. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br. J. Cancer 73 (1996) 610-614
33. Wang Y., Hu J.K., Krol1 A., Li Y.P., Li C.Y., and Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol. Cancer Ther. 2 (2003) 1233-1242
34. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61 (2001) 3501-3507
35. Yotnda P., Chen D.H., Chiu W., Piedra P.A., Davis A., Templeton N.S., and Brenner M.K. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther. 5 (2002) 233-241
36. Young D.C., Kingsley S.D., Ryan K.A., and Dutko F.J. Selective inactivation of eukaryotic beta-galactosidase in assays for inhibitors of HIV-1 TAT using bacterial beta-galactosidase as a reporter enzyme. Anal. Biochem. 215 (1993) 24-30
37. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6 (1999) 113-138